The animal model market is anticipated to be valued US$ 1.7 billion in 2022, growing to US$ 2.9 billion by 2032, representing a 5.5% CAGR between 2022 and 2032.
The animal model market is a critical component of biomedical research, offering invaluable insights into the understanding of diseases, drug development, and therapeutic interventions. Animal models, ranging from rodents to non-human primates, play a pivotal role in studying complex biological processes, testing the efficacy and safety of pharmaceuticals, and advancing medical knowledge. They serve as indispensable tools for researchers and pharmaceutical companies, facilitating the translation of scientific discoveries into clinical applications.
Get Free Sample Copy of This Report-https://www.factmr.com/connectus/sample?flag=S&rep_id=1590
Animal Model Market Dynamics
The dynamics of the animal model market are influenced by several key factors:
- Biomedical Research: Animal models are fundamental to biomedical research, enabling scientists to investigate the genetic, physiological, and behavioral aspects of various diseases. They provide a platform for studying diseases like cancer, cardiovascular disorders, neurological conditions, and infectious diseases.
- Drug Development: Animal models play a crucial role in preclinical drug testing, allowing researchers to assess the safety, efficacy, and potential side effects of new pharmaceutical compounds. This stage is essential in the drug development pipeline before clinical trials in humans.
- Genetic Engineering: Advancements in genetic engineering techniques, such as the creation of transgenic and knockout animals, have expanded the capabilities of animal models, allowing for the study of specific genetic factors in disease development.
- Regulatory Compliance: Regulatory agencies require rigorous testing of new drugs and medical devices in animal models to ensure their safety and effectiveness before human trials. This regulatory compliance drives the demand for animal models in research.
Key Companies Profiled In This Report
- Genoway SA
- Eurofins Scientific SE
- Crown Bioscience Inc.
- Envigo CRS SA
- Transposagen Biopharmaceuticals, Inc.
- Trans Genic Inc.
- The Jackson Laboratory
- Horizon Discovery Group Plc.
- Charles River Laboratories International Inc.
Animal Model Market Value Chain
The animal model market value chain comprises various stakeholders:
- Animal Suppliers: These entities breed and supply laboratory animals, ensuring the availability of diverse animal models to research institutions.
- Research Institutions: Universities, academic research centers, and pharmaceutical companies utilize animal models in their research programs to advance scientific knowledge and drug development.
- Biotechnology and Pharmaceutical Companies: These organizations conduct preclinical studies using animal models to assess the safety and efficacy of potential drug candidates.
- Contract Research Organizations (CROs): CROs specialize in providing preclinical research services, including animal testing, to pharmaceutical companies and research institutions.
- Regulatory Authorities: Regulatory agencies oversee and enforce guidelines and standards for the ethical treatment and use of animals in research.
- Animal Welfare Organizations: These organizations advocate for animal welfare and ethical practices in research, working to ensure the humane treatment of animals in laboratory settings.
Competitive Landscape
In the competitive landscape of the animal model system market, key suppliers are strategically pursuing avenues for expanding their customer base and solidifying their presence in the industry. This is being achieved through a series of acquisitions, mergers, collaborations, and partnerships. Recent investments by major corporations have presented opportunities for the sector to expand its global footprint. Some noteworthy developments include:
Taconic Biosciences and Biomodels Collaboration (April 2022): Taconic Biosciences and Biomodels joined forces to launch the Taconic-Biomodels Microbiome Initiative (TBMI). This initiative provides researchers with streamlined access to comprehensive germ-free and gnotobiotic microbiome study solutions, covering everything from initial design to data analysis. By combining resources and expertise, this collaboration aims to overcome long-standing obstacles in microbiome research, offering access to relevant disease models, germ-free animal production, and comprehensive in-vivo research support.
Inotiv Inc. and Envigo Acquisition (September 2021): Inotiv Inc. entered into an agreement to acquire Envigo, a significant move that strengthens both companies’ capabilities across the entire spectrum of discovery and non-clinical development services. This acquisition enhances their access to a wide range of products and services within a single organization, streamlining the research and development process for their clients.
Get Customization on this Report for Specific Research Solutions –https://www.factmr.com/connectus/sample?flag=RC&rep_id=1590
The animal model market is an integral part of biomedical research and drug development, contributing to scientific advancements and medical breakthroughs. Despite ethical considerations, challenges related to species specificity, and the emergence of alternative methods, animal models remain indispensable for understanding disease mechanisms and advancing healthcare. Researchers and institutions must continue to balance the benefits of animal models with ethical and regulatory responsibilities.
About Fact.MR:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we delivers deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empowers businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
